This clinical trial is focused on studying the effects of a treatment for children with Facial Nerve Palsy, commonly known as Bell’s Palsy. This condition causes sudden weakness or paralysis of the muscles on one side of the face. The study will evaluate the use of a medication called Prednisolone, which is a type of cortisone, to see if it helps improve recovery in affected children. Some participants will receive Prednisolone, while others will receive a placebo, which looks like the medication but does not contain the active substance.

The purpose of the study is to determine how effective cortisone treatment is compared to a placebo in helping children recover from acute facial nerve palsy. Participants in the study will be monitored over a period of 12 months to assess their recovery using a scale called the House-Brackmann scale, which measures the degree of facial nerve function. The study will also look at recovery rates at 1 month and 12 months using another scale called the Sunnybrook grading scale, as well as evaluate the impact of the condition on daily life through various questionnaires.

Throughout the study, the safety of the treatment will be closely monitored by tracking any adverse events. The trial aims to provide valuable information on whether cortisone can be a beneficial treatment option for children experiencing this condition, potentially leading to improved care and outcomes for young patients with facial nerve palsy.